👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

EU, CureVac in talks on 225 million doses of potential COVID-19 vaccine

Published 08/20/2020, 05:53 AM
Updated 08/20/2020, 05:55 AM
© Reuters. EU commissioner for Health, Stella Kyriakides delivers a speech during a press conference on the European Green Deal Biodiversity and Farm to Fork Strategies in Brussels

BRUSSELS (Reuters) - The European Commission said on Thursday it had concluded exploratory talks with CureVac regarding the purchase of 225 million doses of the German biotech firm's potential COVID-19 vaccine.

"Today we concluded talks with the European company CureVac to increase the chances of finding an effective coronavirus vaccine," EU Health Commissioner Stella Kyriakides said.

© Reuters. EU commissioner for Health, Stella Kyriakides delivers a speech during a press conference on the European Green Deal Biodiversity and Farm to Fork Strategies in Brussels

The EU will now begin talks on a contract with CureVac aimed at securing the supply of its potential vaccine for all 27 EU member states should the shot prove safe and effective against COVID-19.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.